Latest News

STAT Plus: Acquisitions, not Congress, will chart biotech’s course in 2020, experts predict 

Washington has never before been so focused on lowering prescription drug prices. But these biotech investors aren’t worried.

“Politics is politics,” Affinity Asset Advisors senior research analyst Patrick Nosker said of drug pricing legislation at a STAT event Tuesday in New York. “The whole political overhang is definitely going to be noise throughout the next year.”

Continue to STAT Plus to read the full story…

Source link

Related posts

Patients with diabetes at increased risk for sleep apnea


USC researchers report breakthrough to prevent osteonecrosis of the jaw


Transabdominal ultrasound and endoscopic ultrasound for diagnosis of gallbladder polyps


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy